HomeTagsPrurigo Nodularis

Prurigo Nodularis

Healthcare

Dupixent Approved by European Commission as the First and Only Targeted Medicine

PR Newswire - December 15, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to...

Biotechnology

Second Positive Phase 3 Dupixent Trial Confirms Significant Improvements for Patients with Prurigo Nodularis

PR Newswire - January 19, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi announced positive pivotal results from a second Phase 3 trial, PRIME, evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo...